Formulary BIOSIMILAR Agents

Caution! Look-Alike Sound-Alike Medications*

Use care when compounding and select the correct product from stock

	Bevacizumab	**Infliximab**	**Trastuzumab**	**Rituximab**	**Pegfilgrastim**	**Filgrastim/tbo-filgrastim**
Preferred product	Zirabev (bevacizumab-bvzr)	Ren**FLEX**is (in**FLIX**imab-abda)	Ogivri (trastuzumab-dkst)	**TRUX**ima (ri**TUX**imab-abbs)	Fulphila (pegfilgrastim-jmdb)	**NIV**estym (filgrastim-aafi)
Secondary product(s)	Mvasi (bevacizumab-awwb)	In**FLEC**tra (in**FLIX**imab-dyyb)	Kanjinti (trastuzumab-anns)	**RUXI**ence (ri**TUX**imab-pvvr) *Or* Riabni (ri**TUX**imab-arrx)	None on formulary	None on formulary
Reference (tertiary) product	Avastin	**REM**icade	Herceptin	RI**TUX**an	None on formulary	None on formulary

Biosimilar products are <u>NOT</u> interchangeable

Examples:

1. If Ruxience is ordered, cannot mix and dispense Truxima without getting a new order.
2. If Renflexis is ordered, cannot mix and dispense Inflectra
3. If Kanjinti is ordered, cannot mix and dispense Ogivri

New Inpatient orders	Biosimilars should *always* be utilized over a reference product.
New Outpatient infusion orders	Biosimilars should be utilized *unless* the insurance payer does not approve use

Updated Dec 2021